SPR announced positive results from its MONARCH study, which investigated the use of its SPRINT PNS System for treating occipital neuralgia and cervicogenic headache. The study found that 90% of participants experienced clinically significant pain reduction after 60 days of treatment, with 85% experiencing substantial pain reduction. The study also demonstrated a strong safety profile, with no serious or unexpected adverse events.
This news is potentially impactful for patients suffering from these debilitating headache conditions. Current treatment options often involve medications with potential side effects or invasive procedures. The SPRINT PNS System offers a non-opioid, minimally invasive alternative that could significantly improve quality of life for these individuals by reducing both pain levels and interference with daily activities. The high percentage of patients achieving clinically significant pain reduction suggests this technology could become a valuable tool for managing these challenging conditions.
The MONARCH study, published in the journal •Headache•, demonstrated the efficacy and safety of the 60-day SPRINT PNS treatment. All 20 participants reported at least minimal improvement, and the majority experienced sustained pain reduction even after the treatment period. Observed adverse events were mild or moderate and primarily consisted of skin irritation.
These positive results strengthen SPR’s position in the neuromodulation market and expand the potential applications of the SPRINT PNS System. This could lead to increased adoption by healthcare providers, offering a promising new option for patients seeking relief from chronic headache pain. Further research and real-world data will be crucial for confirming the long-term benefits and solidifying the system’s role in headache management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
